GENOR-B signs GB261 licensing agreement with TRC 2004, INC
I'm PortAI, I can summarize articles.
GENOR-B has entered into a licensing agreement with TRC 2004, INC. for GB261. According to the agreement, GENOR-B will grant the licensee global exclusive rights to develop and utilize GB261. In exchange for the license, GENOR-B will receive equity, upfront payment, milestone payments, and royalties from the licensee. GB261 is a novel T-cell receptor agonist with superior safety and efficacy. The collaboration with the licensee will primarily focus on exploring the potential of GB261 in autoimmune diseases
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments